Marksans Pharma (MARKSANS) — Board Meeting

1 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
34th AGM adopts FY2026 financials and declares 90% dividend

🔄 What Changed
Adoption of audited standalone and consolidated financial statements for FY2026

🔮 What's Next
Re-appointment of Mrs. Sandra Saldanha as Whole-time Director for three years effective 25 September 2026

💡 Investor Takeaway
The dividend declaration and director re-appointment signal confidence in financial performance and governance continuity.

Marksans Pharma held its 34th AGM on 27 August 2026 via video conference, adopting audited standalone and consolidated financial statements for FY2026, declaring a 90% dividend of Rs. 0.90 per share, and approving the re-appointment of Mrs. Sandra Saldanha as Whole-time Director for three years. Shareholders expressed satisfaction with performance and raised queries clarified by the Chairman.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
All four AGM resolutions passed with majority votes via remote e-voting and in-person voting.

🔄 What Changed
Adoption of audited financial statements, declaration of Rs.0.90 dividend, reappointment of Dr. Sunny Sharma and Mrs. Sandra Saldanha as directors.

🔮 What's Next
None

💡 Investor Takeaway
Shareholders approved key governance and financial decisions, including dividend payout and director appointments, signaling confidence in the company's financial position and leadership continuity.

Marksans Pharma shareholders approved all four AGM resolutions via remote e-voting and in-person voting on August 27, 2026. The audited standalone and consolidated financial statements for FY2026 were adopted, a final dividend of Rs.0.90 per share was declared, Dr. Sunny Sharma was reappointed as director, and Mrs. Sandra Saldanha was reappointed as whole-time director for three years starting September 25, 2026. Voting results show overwhelming approval across all resolutions with minimal dissent.

📊 Stock Analysis — MARKSANS ✨ Ask AI About This

About Marksans Pharma Ltd (MARKSANS)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹14,634.92 Cr P/E: 28.3 ROE: 17.2% ROCE: 23.4% Div Yield: 0.28%

View full MARKSANS stock details →

📡 Get AI alerts when MARKSANS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MARKSANS — Free

💡 Ask AI about this filing

"What is the FY2026 revenue and profit growth?" "How does the 90% dividend compare to peers?" "What are the risks in reappointing Mrs. Saldanha?"

Ask AI Free →

📊 More MARKSANS filings

See all MARKSANS filings →

🔥 Also filed on 27 August 2026

JNPR Juniper Green Energy Ltd Financial Results AWFIS AWFIS Space Solutions Ltd Annual Report 509084 Photon Capital Advisors Ltd Annual Report GUJALKALI Gujarat Alkalies & Chemicals Ltd Annual Report EPACK Epack Durable Ltd Annual Report 538546 Bansal Roofing Products Ltd Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MARKSANS files new disclosures

Track MARKSANS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MARKSANS — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd

Marksans Pharma Ltd (MARKSANS) — Board Meeting | 27 August 2026(2 announcements)

About Marksans Pharma Ltd (MARKSANS)

📡 Get AI alerts when MARKSANS files next

💡 Ask AI about this filing

📊 More MARKSANS filings

🔥 Also filed on 27 August 2026